Publications by authors named "A M Orbai"
Objective: The aim of this analysis was to evaluate the relationship between the criteria met of the Minimal Disease Activity (MDA) score for psoriatic arthritis (PsA) and patient-perceived disease status.
Methods: We analysed data from the ReFlaP study (NCT03119805), a cross-sectional international study of adult patients with PsA. Patients self-reported if they felt their PsA was in remission (REM), low disease activity (LDA) or neither.
Article Synopsis
- The study aimed to determine effective cutoff scores for the Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) based on disease activity measures in patients with PsA.
- Using data from the ReFlaP study, researchers analyzed scores to define disease states such as remission and varying impact levels, employing statistical methods to establish these cutoffs.
- Results indicated that the PsAID12 score had high diagnostic performance against established benchmarks, but further validation and expert consensus are needed to confirm the proposed cutoffs for clinical use.
Objective: Adaptive immunity mediates psoriatic disease pathogenesis. We aimed to identify novel psoriatic autoantigens and their phenotypic associations in deeply characterized patient cohorts.
Methods: Sera from psoriatic arthritis (PsA) patients were used for autoantibody discovery.
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group provided updates at the GRAPPA 2023 annual meeting on its work to evaluate composite outcome measures for PsA. An ongoing systematic literature review is in progress to evaluate psychometric measurement properties using the OMERACT filter 2.2 for a list of candidate composite outcome measures, which include minimal disease activity (MDA), Disease Activity for Psoriatic Arthritis (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (3VAS), and 4VAS.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the efficacy of bimekizumab for treating Psoriatic Arthritis (PsA) from the patient's perspective using the PsA Impact of Disease (PsAID-12) questionnaire after one year of treatment.
- The analysis involved 1,112 patients across different trials, showing that those treated with bimekizumab experienced significant and lasting improvements in disease symptoms starting as early as Week 4 and continuing to 1 year.
- Results indicated that a notable percentage of patients reported minimal or no symptom impact after a year, with improvements noted in various areas such as pain, fatigue, and skin issues.